Bay-Jensen Anne C, Karsdal Morten A, Vassiliadis Efstathios, Wichuk Stephanie, Marcher-Mikkelsen Kathrine, Lories Rik, Christiansen Claus, Maksymowych Walter P
Department of Rheumatology, Nordic Bioscience, Herlev, Denmark.
Arthritis Rheum. 2013 Apr;65(4):972-80. doi: 10.1002/art.37843.
Ankylosing spondylitis (AS) has been considered a seronegative rheumatic disease based on absent or low levels of antibodies against citrullinated proteins. The present study was undertaken to evaluate whether a citrullinated and matrix metalloproteinase-degraded fragment of vimentin (VICM) could be a prognostic biomarker in AS.
VICM was measured in serum samples from healthy controls (n=35), control patients with rheumatoid arthritis (RA) (n=47), and patients with AS (n=201). The optimal cutoff for diagnostic sensitivity and specificity was determined by receiver operating characteristic curve analysis. Baseline and 2-year spine radiographs were available from 118 AS patients, and were scored using the modified Stoke AS Spine Score (mSASSS). We assessed correlations with patient demographic characteristics (age, disease duration), disease activity (Bath AS Disease Activity Index [BASDAI], C-reactive protein level), and disease severity (mSASSS) using Spearman's rho. The independent association of VICM with 2-year radiographic progression, defined as a change of >0 in the mSASSS or the development of a new syndesmophyte, was analyzed by multivariate regression.
Levels of degraded VICM were significantly higher in both RA patients and AS patients than in healthy controls (both P<0.001). AS patients with the highest levels of VICM had the largest burden of disease (P<0.01), i.e., highest mSASSS score and BASDAI. VICM levels were significantly and independently associated with radiographic progression after 2 years (β=0.69, P=0.0005). Patients with both a high VICM level and a high baseline mSASSS had the highest risk of radiographic progression (odds ratio 13 for mSASSS change, 32 for new syndesmophytes), with progression occurring in 67% of these patients.
The present findings show that serum VICM may be of prognostic value in AS. The data also suggest that citrullination may be relevant in AS pathogenesis.
基于抗瓜氨酸化蛋白抗体缺乏或水平较低,强直性脊柱炎(AS)一直被视为血清阴性的风湿性疾病。本研究旨在评估波形蛋白的瓜氨酸化和基质金属蛋白酶降解片段(VICM)是否可作为AS的预后生物标志物。
检测了健康对照者(n = 35)、类风湿关节炎(RA)对照患者(n = 47)和AS患者(n = 201)血清样本中的VICM。通过受试者工作特征曲线分析确定诊断敏感性和特异性的最佳临界值。118例AS患者有基线和2年的脊柱X线片,采用改良斯托克强直性脊柱炎脊柱评分(mSASSS)进行评分。我们使用斯皮尔曼等级相关系数评估了与患者人口统计学特征(年龄、病程)、疾病活动度(巴斯强直性脊柱炎疾病活动指数[BASDAI]、C反应蛋白水平)和疾病严重程度(mSASSS)的相关性。通过多变量回归分析VICM与2年影像学进展的独立关联,2年影像学进展定义为mSASSS变化>0或出现新的韧带骨赘。
RA患者和AS患者中降解的VICM水平均显著高于健康对照者(均P<0.001)。VICM水平最高的AS患者疾病负担最大(P<0.01),即mSASSS评分和BASDAI最高。VICM水平与2年后的影像学进展显著且独立相关(β = 0.69,P = 0.0005)。VICM水平高且基线mSASSS高的患者影像学进展风险最高(mSASSS变化的优势比为13,新韧带骨赘的优势比为32),这些患者中有67%出现进展。
本研究结果表明,血清VICM可能对AS具有预后价值。数据还表明,瓜氨酸化可能与AS发病机制相关。